Ubrogepant, also known as MK-1602, is a potent and selective oral calcitonin gene-related peptide (CGRP) receptor antagonist. Ubrogepant, sold under the trade name Ubrelvy, is a medication used for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. It is not indicated for the preventive treatment of migraine. It is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine. In December 2019, the U.S. Food and Drug Administration approved Ubrelvy produced by Allergan USA, Inc. for treatment of migraine after onset.
Belyk, Kevin M.; Cleator, Edward; Kuo, Shen-Chun; Maligres, Peter Emmanuel; Xiang, Bangping; Yasuda, Nobuyoshi; Yin, Jianguo. Process for preparing pyrrolo[2,3-b]pyridine derivatives as CGRP receptor antagonists. Assignee Merck Sharp & Dohme Corp., USA. 2013. WO 2013138418.
Bell, Ian M.; Fraley, Mark E.; Gallicchio, Steven N.; Ginnetti, Anthony; Mitchell, Helen J.; Paone, Daniel V.; Staas, Donnette D.; Wang, Cheng; Zartman, C. Blair; Stevenson, Heather E. Preparation of piperidinonylcarboxamideazaindane derivatives for use as CGRP receptor antagonists. Assignee Merck Sharp & Dohme Corp., USA. 2012. WO 2012064910.
